B-RAF with PLX4032: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (21 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==B-RAF with PLX4032== | ==B-RAF with PLX4032== | ||
PLX4032 is a newly synthesized drug that is being used to treat malignant | PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF. | ||
<scene name='B-RAF_with_PLX4032/Plx_4032_only/ | <applet load='3og7' size='400' color='white' frame='true' align='right' caption='BRAF kinase domain complex with PLX4032 (PDB code [[3og7]])' /> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/Plx_4032_only/2'>PLX 4032</scene><br> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/Atp/2'>ATP</scene><br> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/Wild-type_b-raf/2'>Wild-Type B-RAF</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/Mutated_v600e/2'>V600E Mutation</scene> <br> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/H-bond/4'>H-Bond Interaction Asp594 and PLX4032</scene><br> | ||
<scene name='B-RAF_with_PLX4032/ | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/4'>Superposition overview</scene> <br> | ||
< | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/5'>Superposition close up</scene> <br> | ||
< | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/2'>Superposition active site</scene> <br> | ||
Latest revision as of 12:49, 3 January 2019
B-RAF with PLX4032B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
|
